The HPV vaccine, historically marketed for cervical cancer prevention in women, reduces cancer risk in men by 42-50% when vaccinated between ages 9-26, with some studies showing reductions as high as 70% in certain populations. This finding supports broader adoption of gender-neutral vaccination programs. The article links to CNN's full reporting but the headline itself accurately reflects the verified science without overstating the benefit.